Clinical Study
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis
Table 4
Adverse events during the treatments.
| Adverse events (AEs) | Number of the patients | Serious AEs resulting in drug withdrawal |
| Infliximab group () | Infusion reaction | 1 | 1 | Delayed hypersensitivity reaction | 1 | 1 | Leukocytopenia | 1 | 1 | Anemia | 2 | 0 | Pneumonia | 2 | 2 | Idiopathic thrombocytopenic purpura | 1 | 1 | Total | 8 | 6 (12.5%) |
| Tacrolimus group () | Renal dysfunction | 8 | 1 | Hot flushes | 4 | 0 | Tremor | 4 | 0 | Headache | 5 | 0 | Hypomagnesemia | 5 | 0 | Liver dysfunction | 1 | 1 | Total | 27 | 2 (4.3%) |
|
|